Povidone-Iodine Rinses in the Management of COVID-19

• Status: Not yet recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine if Povidone iodine (PVP-I) rinses and throat gargles or a PVP-I gel forming nasal spray compared to a placebo (a treatment that has no physical effect to a person) is an effective treatment for patients diagnosed with COVID-19. These patients have been diagnosed with mild/moderate COVID-19 symptoms and sent home for self-isolation. Patients will be instructed to take either of the two treatments or placebo twice daily for two weeks and have follow up visits 2 and 4 weeks after. The participants will also complete study related procedures such as saliva sample collection, and two questionnaires throughout the study period. The investigators hypothesize that COVID 19 positive participants who use either of the Povidone - Iodine treatment will have a reduction in their viral load, develop a negative oral mucosa sample and improve their clinical symptoms.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Paul's Hospital, Canada
• Treatments: Povidone; Povidone-Iodine

Criteria

Inclusion Criteria:

• 19 years or older

• Patients diagnosed with laboratory-confirmed SARS-CoV-2 and the development of COVID-19 compatible symptoms within the last 72 hours before enrolment

• Do not require hospitalization

Exclusion Criteria:

• Sinonasal tumor

• Hypersensitivity to iodine or betadine

• History of thyroid disorder including thyroid cancer, hyperthyroidism and hypothyroidism

• Use of medications for thyroid disorders including thyroxine and carbimazole

• Current use of topical iodine or betadine for another reason

• Participating in any study with therapies directed at COVID-19 that could influence our results

• Are pregnant or breastfeeding